[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20071655L - Malrettet levering av lidocaine og andre lokale bedovelsesmidler og en fremgangsmate for behandling av hoste og tussivangrep - Google Patents

Malrettet levering av lidocaine og andre lokale bedovelsesmidler og en fremgangsmate for behandling av hoste og tussivangrep

Info

Publication number
NO20071655L
NO20071655L NO20071655A NO20071655A NO20071655L NO 20071655 L NO20071655 L NO 20071655L NO 20071655 A NO20071655 A NO 20071655A NO 20071655 A NO20071655 A NO 20071655A NO 20071655 L NO20071655 L NO 20071655L
Authority
NO
Norway
Prior art keywords
lidocaine
targeted delivery
treating cough
nebulized
local anesthetics
Prior art date
Application number
NO20071655A
Other languages
English (en)
Inventor
Alan Bruce Montgomery
Thomas Hofmann
Kevin Stapleton
Original Assignee
Corus Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corus Pharma Inc filed Critical Corus Pharma Inc
Publication of NO20071655L publication Critical patent/NO20071655L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives en antitussiv nebulisert løsning for målrettet avlevering av lidokain til ledende og sentrale luftveier, en fremgangsmåte for behandling av hoste og hosteanfall eller -episoder ved bruk av nevnte lidokainløsning, en nebulisert lidokainløsning administrert i døgndoser på fra 10 mg til 80 mg lidokain løst i saltvann og nebulisert til en aerosol som har en massemedian aerodynamisk diameter på 3 ?m til 10 ?m og et geometrisk standardavvik lavere enn 1,7, ved å benytte en elektronisk nebulisator.
NO20071655A 2004-09-20 2007-03-29 Malrettet levering av lidocaine og andre lokale bedovelsesmidler og en fremgangsmate for behandling av hoste og tussivangrep NO20071655L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61165604P 2004-09-20 2004-09-20
US63502204P 2004-12-09 2004-12-09
PCT/US2005/002555 WO2006036180A1 (en) 2004-09-20 2005-01-28 Targeted delivery of lidocaine and other local anesthetics and a method for treatment of cough and tussive attacks

Publications (1)

Publication Number Publication Date
NO20071655L true NO20071655L (no) 2007-06-19

Family

ID=36119205

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20071655A NO20071655L (no) 2004-09-20 2007-03-29 Malrettet levering av lidocaine og andre lokale bedovelsesmidler og en fremgangsmate for behandling av hoste og tussivangrep
NO20071654A NO20071654L (no) 2004-09-20 2007-03-29 Fremgangsmate for a forbedre toleransen for terapeutiske effektive midler levert ved inhalering

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20071654A NO20071654L (no) 2004-09-20 2007-03-29 Fremgangsmate for a forbedre toleransen for terapeutiske effektive midler levert ved inhalering

Country Status (7)

Country Link
US (1) US20060062739A1 (no)
EP (1) EP1796637A4 (no)
JP (2) JP2008513445A (no)
AU (1) AU2005290312A1 (no)
CA (1) CA2581209A1 (no)
NO (2) NO20071655L (no)
WO (2) WO2006036181A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008514648A (ja) * 2004-12-16 2008-05-08 アドバンスト インハレーション リサーチ，インコーポレイテッド 肺疾患のための組成物および方法
EP2425858A3 (en) 2006-11-20 2012-03-28 President and Fellows of Harvard College Compositions for treating pain and pruritus
JP2008259704A (ja) * 2007-04-12 2008-10-30 Hisamitsu Pharmaceut Co Inc プレフィルド型シリンジ
EP2203057A4 (en) 2007-09-20 2010-09-29 Univ Rochester METHODS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF INFLAMMATORY CONDITIONS
AU2010229668C1 (en) * 2009-03-26 2016-09-15 Pulmatrix Operating Co., Inc. Dry powder formulations and methods for treating pulmonary diseases
CA2767646C (en) * 2009-07-10 2019-01-29 President And Fellows Of Harvard College Permanently charged sodium and calcium channel blockers as anti-inflammatory agents
WO2017024037A1 (en) 2015-08-03 2017-02-09 President And Fellows Of Harvard College Charged ion channel blockers and methods for use
US10828287B2 (en) 2019-03-11 2020-11-10 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
KR20210145166A (ko) 2019-03-11 2021-12-01 녹시온 테라퓨틱스 인코포레이티드 하전된 이온 채널 차단제 및 사용 방법
US10780083B1 (en) 2019-03-11 2020-09-22 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
CA3129131A1 (en) 2019-03-11 2020-09-17 Bridget Mccarthy Cole Charged ion channel blockers and methods for use
EP3937934A4 (en) 2019-03-11 2022-11-09 Nocion Therapeutics, Inc. ESTER-SUBSTITUTED ION CHANNEL BLOCKERS AND METHODS OF USE
EP3956002A4 (en) * 2019-04-18 2023-01-25 Jon Greenfield POSITIVE PRESSURE INHALER FOR DELIVERY OF INHALED MEDICATIONS AND METHODS OF USE
US10933055B1 (en) 2019-11-06 2021-03-02 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
CN114828845A (zh) 2019-11-06 2022-07-29 诺西恩医疗公司 带电的离子通道阻滞剂及其使用方法
EP4118070A4 (en) 2020-03-11 2024-04-10 Nocion Therapeutics, Inc. CHARGED ION CHANNEL BLOCKERS AND METHODS OF USE
CN111632024B (zh) * 2020-07-02 2021-12-31 渠静 一种局麻药制剂及其制备方法、应用
EP4262764A4 (en) 2020-12-17 2024-11-13 Incarda Therapeutics Inc KITS AND METHODS FOR INDUCING CARDIOVERSION IN PERSONS WITH ATRIAL ARRHYTHMIA

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837713A (en) * 1997-02-26 1998-11-17 Mayo Foundation For Medical Education And Research Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids
KR20010072593A (ko) * 1998-06-09 2001-07-31 추후보정 기침 치료용 조성물 및 기침 치료방법
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
IL153574A0 (en) * 2000-06-23 2003-07-06 Mayo Foundation Methods of treating neutrophil-related diseases with topical anesthetics
MXPA04003879A (es) * 2001-10-24 2005-02-17 Pari Gmbh Equipo para la preparacion de una composicion farmaceutica.
AU2003215334A1 (en) * 2002-02-22 2003-09-09 Advanced Inhalation Research, Inc. Inhalable formulations for sustained release

Also Published As

Publication number Publication date
JP2008513445A (ja) 2008-05-01
NO20071654L (no) 2007-06-19
WO2006036181A1 (en) 2006-04-06
AU2005290312A1 (en) 2006-04-06
EP1796637A4 (en) 2010-01-13
EP1796637A1 (en) 2007-06-20
JP2008513444A (ja) 2008-05-01
US20060062739A1 (en) 2006-03-23
WO2006036180A1 (en) 2006-04-06
CA2581209A1 (en) 2006-04-06

Similar Documents

Publication Publication Date Title
NO20071655L (no) Malrettet levering av lidocaine og andre lokale bedovelsesmidler og en fremgangsmate for behandling av hoste og tussivangrep
Wilson et al. Airborne transmission of severe acute respiratory syndrome coronavirus‐2 to healthcare workers: a narrative review
MEP30208A (en) Pressurised metered dose inhalers containing solutions of beta-2 agonists
RU2016101054A (ru) Комбинации лекарственных средств и их применение в лечении состояния, сопровождающегося кашлем
US8709496B2 (en) Use of deuterium oxide for the treatment of virus-based diseases of the respiratory tract
Aguila et al. Repurposed GI drugs in the treatment of COVID-19
CN101967204B (zh) 太子参多糖在润肺镇咳中的应用
WO2007047372A3 (en) Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists
Fan et al. Cepharanthine: A Promising Old Drug against SARS‐CoV‐2
WO2006060027A3 (en) A method for improvement of tolerance for therapeutically effective agents delivered by inhalation
NO20044001L (no) Aerosolformulering for inhalasjon omfattende et tiotropiumsalt
Lema et al. Evidence-based perioperative management of a child with upper respiratory tract infections (URTIs) undergoing elective surgery; A systematic review
Cook et al. Reduced adverse event profile of orally inhaled DHE (MAP0004) vs IV DHE: potential mechanism
Elcock et al. Sevoflurane vs. isoflurane: a clinical comparison in day surgery
Charuni Narrative review on the spectrum of diseases prevalent among substance-addicted populations and their interconnected health dynamics
WO2005107768A3 (en) Method for improving ventilatory efficiency
Michels et al. Comparison of drug abuse in Germany and China 1
Shohrati et al. N-acetyl cysteine effect on sleep quality and respiratory function of morphine addicts in treatment period a pilot study
Shu et al. Efficacy and Safety of Re Du Ning Injection for Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta‐Analysis
Holmes et al. Chronic model of sulfur mustard‐induced lung injury in Fischer 344 rats
DK202170549A1 (en) Medicament for inhalation or breathing, and inhaler or breathing device comprising same
EP0998928A4 (en) Cough medium
Kang et al. Analysis of physicochemical properties for the biopharmaceuticals to overcome COVID-19
Ren et al. Effects of ultrasound-guided QLB and ESPB on postoperative recovery quality and analgesia in elderly patients with colorectal cancer
Thomas et al. Characterization of pediatric extrathoracic aerosol deposition with air-jet dry powder inhalers

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application